Oxford BioDynamics Plc (OBD) Stock Discussion | Share discussion

Oxford BioDynamics Plc

Oxford BioDynamics PLC provides biotechnology services.

Industry: Life Sciences Tools & Services

Ticker	Exchange	ISIN
$OBD	LSE AIM	GB00BD5H8572

Recent news

Carnival Net Income dropped on 442% and Revenue dropped on 73.1%

Unisys Corp reports 4,465% Net Income growth in 2020 while 31.3% Revenue decline

Northamber Net Income surged on 1,523%

International Bus Mach Corp reports 40.7% Net Income decline in 2020 and 3.2 pp EBITDA Margin decline from 20.7% to 17.5%

Blue Prism Group plc revenue surged on 40% and EBITDA Margin surged on 28.9 pp from -78.3% to -49.4%

Tui Ag EBITDA dropped on 220% and Revenue dropped on 58.0%

Zytronic Net Income dropped on 111% and EBITDA Margin dropped on 15.0 pp from 20.6% to 5.6%

Image Scan Hldgs revenue surged on 47.3% and EBITDA Margin surged on 21.0 pp from -16.0% to 5.0%

Oxford Metrics Net Income dropped on 61.6% and Revenue dropped on 14.3%

I-Nexus Global Plc revenue dropped on 14.3%

Twit about OBD stock

Share your investment idea or question on Oxford BioDynamics Plc stock:

Latest twits on Oxford BioDynamics Plc (OBD)

No twits yet. Be the first to post!

Have a question about OBD? Ask and other investors will be eager to help you.

Have an idea about OBD? Share it with other investors.

Oxford BioDynamics Plc news

10 Dec 2019 Oxford BioDynamics Plc revenue dropped on 23.5% and EBITDA Margin dropped on 176 pp from -191% to -368%

11 Dec 2018 Oxford BioDynamics Plc reports 3.3% CAPEX growth in 2018 and almost no change in Revenue of 1.2

Oxford BioDynamics Plc stock price chart

Oxford BioDynamics Plc financials

mln. £	FY2013	FY2014	FY2015

Revenue	0.350	0.659	0.702
EBITDA	-0.973	-0.717	-1.170
Net income	-1.055	-0.736	-1.005
CAPEX	0.111	0.038	0.523
Debt	0.000	0.000	0.000
Cash	3.018	5.498	8.435

Oxford BioDynamics Plc news

About Oxford BioDynamics Plc

Oxford BioDynamics PLC provides biotechnology services. The Company offers drugs discovery and development for diagnostics and residual disease monitoring of breast, liver, prostate, and thyroid cancers. Oxford BioDynamics conducts its business in the United Kingdom and Malaysia.